161 related articles for article (PubMed ID: 37262305)
41. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides.
Delfau-Larue MH; Dalac S; Lepage E; Petrella T; Wechsler J; Farcet JP; Bagot M
Blood; 1998 Nov; 92(9):3376-80. PubMed ID: 9787176
[TBL] [Abstract][Full Text] [Related]
42. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
Kim YH; Martinez G; Varghese A; Hoppe RT
Arch Dermatol; 2003 Feb; 139(2):165-73. PubMed ID: 12588222
[TBL] [Abstract][Full Text] [Related]
43. Expression of CD31 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Grzegrzolka J; Piotrowska A; Gomulkiewicz A; Glatzel-Plucinska N; Olbromski M; Podhorska-Okolow M; Szepietowski JC; Dziegiel P
Anticancer Res; 2016 Sep; 36(9):4575-82. PubMed ID: 27630298
[TBL] [Abstract][Full Text] [Related]
44. Skin directed therapy for mycosis fungoides: a review.
Berthelot C; Rivera A; Duvic M
J Drugs Dermatol; 2008 Jul; 7(7):655-66. PubMed ID: 18664158
[TBL] [Abstract][Full Text] [Related]
45. Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis.
Lindahl LM; Fenger-Gron M; Iversen L
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):163-8. PubMed ID: 22229501
[TBL] [Abstract][Full Text] [Related]
46. High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides.
de Masson A; O'Malley JT; Elco CP; Garcia SS; Divito SJ; Lowry EL; Tawa M; Fisher DC; Devlin PM; Teague JE; Leboeuf NR; Kirsch IR; Robins H; Clark RA; Kupper TS
Sci Transl Med; 2018 May; 10(440):. PubMed ID: 29743350
[TBL] [Abstract][Full Text] [Related]
47. Mycosis fungoides: a dermatological masquerader.
Nashan D; Faulhaber D; Ständer S; Luger TA; Stadler R
Br J Dermatol; 2007 Jan; 156(1):1-10. PubMed ID: 17199560
[TBL] [Abstract][Full Text] [Related]
48. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
49. Chlormethine gel in combination with other therapies for treatment of mycosis fungoides: a review with patient cases.
Ardigò M; Nikbakht N; Teoli M; Gleason L; Crisan L; Querfeld C
Front Med (Lausanne); 2023; 10():1308491. PubMed ID: 38274457
[TBL] [Abstract][Full Text] [Related]
50. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.
Kim YH; Chow S; Varghese A; Hoppe RT
Arch Dermatol; 1999 Jan; 135(1):26-32. PubMed ID: 9923777
[TBL] [Abstract][Full Text] [Related]
51. Updated review on prognostic factors in mycosis fungoides and new skin lymphoma trials.
Farabi B; Seminario-Vidal L; Jamgochian M; Akay BN; Atak MF; Rao BK; Karagaiah P; Grabbe S; Goldust M
J Cosmet Dermatol; 2022 Jul; 21(7):2742-2748. PubMed ID: 34687485
[TBL] [Abstract][Full Text] [Related]
52. Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences.
Geskin LJ; Angello JT; Bagot M; Guenova E; Nikbakht N; Querfeld C; Scarisbrick JJ
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):40-47. PubMed ID: 37802679
[TBL] [Abstract][Full Text] [Related]
53. Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides.
Alexander-Savino CV; Chung CG; Gilmore ES; Carroll SM; Poligone B
Dermatol Ther (Heidelb); 2022 Mar; 12(3):643-654. PubMed ID: 35122614
[TBL] [Abstract][Full Text] [Related]
54. Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.
Wu PA; Huang V; Bigby ME
Br J Dermatol; 2014 May; 170(5):1015-20. PubMed ID: 24841586
[TBL] [Abstract][Full Text] [Related]
55. [Modern therapy of mycosis fungoides].
Roenigk HH
Hautarzt; 1983 Jun; 34(6):266-72. PubMed ID: 6874333
[TBL] [Abstract][Full Text] [Related]
56. Milia in regressing plaques of mycosis fungoides: provoked by topical nitrogen mustard or not?
Kalayciyan A; Oguz O; Demirkesen C; Serdaroglu S; Kotogyan A
Int J Dermatol; 2004 Dec; 43(12):953-6. PubMed ID: 15569030
[TBL] [Abstract][Full Text] [Related]
57. Cutaneous T-cell lymphoma: practical recommendations to enhance clinical practice.
Howles A; Scarisbrick J
Br J Hosp Med (Lond); 2021 Mar; 82(3):1-6. PubMed ID: 33792384
[TBL] [Abstract][Full Text] [Related]
58. Increased Chlormethine-Induced DNA Double-Stranded Breaks in Malignant T Cells from Mycosis Fungoides Skin Lesions.
Chang YT; Ignatova D; Hoetzenecker W; Pascolo S; Fassnacht C; Guenova E
JID Innov; 2022 Jan; 2(1):100069. PubMed ID: 34977846
[TBL] [Abstract][Full Text] [Related]
59. Transcriptomic changes during stage progression of mycosis fungoides.
Xiao MZX; Hennessey D; Iyer A; O'Keefe S; Zhang F; Sivanand A; Gniadecki R
Br J Dermatol; 2022 Mar; 186(3):520-531. PubMed ID: 34528236
[TBL] [Abstract][Full Text] [Related]
60. Papular mycosis fungoides: a new clinical variant of early mycosis fungoides.
Kodama K; Fink-Puches R; Massone C; Kerl H; Cerroni L
J Am Acad Dermatol; 2005 Apr; 52(4):694-8. PubMed ID: 15793526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
